|
|
Volumn 349, Issue 3, 2003, Pages 213-214
|
|
A big study yields big questions
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ESTROGEN;
PROGESTERONE;
PROSTATE SPECIFIC ANTIGEN;
SEX HORMONE;
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
FINASTERIDE;
STEROID 5ALPHA REDUCTASE;
BREAST CANCER;
CALCULATION;
CANCER RESEARCH;
CANCER SCREENING;
CARDIOVASCULAR RISK;
COLON CANCER;
DRUG SAFETY;
FINANCIAL MANAGEMENT;
HEART INFARCTION;
HIP FRACTURE;
HORMONAL THERAPY;
HORMONE SUBSTITUTION;
HUMAN;
MEDICAL LITERATURE;
MEDICAL RESEARCH;
MENOPAUSAL SYNDROME;
POSTMENOPAUSE;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROSTATE HYPERTROPHY;
REVIEW;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
SEXUAL DYSFUNCTION;
SIDE EFFECT;
STROKE;
SYMPTOM;
TAX;
TUMOR BIOPSY;
BLOOD;
CLINICAL TRIAL;
DRUG ANTAGONISM;
MALE;
NOTE;
PROSTATE TUMOR;
RISK;
ANTINEOPLASTIC AGENTS, HORMONAL;
CLINICAL TRIALS;
FINASTERIDE;
HUMANS;
MALE;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
RISK;
TESTOSTERONE 5-ALPHA-REDUCTASE;
|
|
EID: 0038340257
PISSN: 00284793
EISSN: None
Source Type: Journal
DOI: 10.1056/NEJMp038121 Document Type: Review |
|
Times cited : (12)
|
|
References (0)
|
